CLINICAL RESEARCH: LEFT VENTRICULAR MASS IN CARDIAC DISEASE
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction
A substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial
Eva Lonn, MD, MSc, FACC, FRCPC* ,*,
Roya Shaikholeslami, MD*,
Qilong Yi, PhD ,
Jackie Bosch, MSc,
Brian Sullivan, MD, FRCPC*,
Paul Tanser, MD, FACC, FRCPC*,
Alison Magi, RN and
Salim Yusuf, MBBS, DPhil, FACC, FRCPC*
* Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
Princess Margaret Hospital, Toronto, Ontario, Canada
Manuscript received July 14, 2003;
revised manuscript received October 22, 2003,
accepted October 27, 2003.
* Reprint requests and correspondence: Dr. Eva Lonn, Hamilton Health Sciences Corporation, General Site, 237 Barton Street East, Hamilton, Ontario, Canada, L8L 2X2.
lonnem{at}mcmaster.ca
OBJECTIVES: The purpose of this study was to assess the effects of ramipril on left ventricular mass (LVM) and function in vascular disease patients with controlled blood pressure (BP) and with preserved left ventricular ejection fraction (LVEF).
BACKGROUND: Increased LVM and left ventricular (LV) volume and decreased LVEF predict clinical events. Angiotensin-converting enzyme inhibitors reduce LVM and LV volume and preserve LVEF in patients with hypertension and/or LV dysfunction, but have not been studied in patients with controlled BP and preserved LVEF.
METHODS: We compared the effects of two doses of ramipril (10 mg/day and 2.5 mg/day) versus placebo in 506 patients with vascular disease on echocardiographic measures of LVM and LV function.
RESULTS: Baseline BP and LVEF were similar, 131/76 mm Hg and 58%, in all treatment groups. After four years, LVM index increased by 3.98 ± 2.08 g/m2 in the placebo and by 4.16 ± 1.86 g/m2 in the ramipril 2.5 mg/day groups and decreased by 2.02 ± 2.25 g/m2 in the ramipril 10 mg/day group (p = 0.02). The changes in LV end-diastolic and end-systolic volumes were 4.16 ± 2.55 ml and 5.31 ± 1.67 ml in the placebo, –0.43 ± 2.75 ml and 2.90 ± 1.45 ml in the ramipril 2.5 mg/day, and –5.90 ± 2.93 ml and –1.90 ± 1.55 ml in the ramipril 10 mg/day groups (p = 0.02 and p = 0.001). The changes in LVEF were –2.02 ± 0.72%, –1.54 ± 0.74%, and –0.17 ± 0.72%, respectively (p = 0.01).
CONCLUSIONS: Ramipril has beneficial effects on LV structure and function in vascular patients with controlled BP and with preserved LVEF.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ASE | = American Society of Echocardiography | | BP | = blood pressure | | HOPE | = Heart Outcomes Prevention Evaluation trial | | LV | = left ventricle/ventricular | | LVEDV | = left ventricular end-diastolic volume | | LVEF | = left ventricular ejection fraction | | LVESV | = left ventricular end-systolic volume | | LVM | = left ventricular mass | | LVMI | = left ventricular mass index | | NWMAB | = new wall motion abnormalities | | WMS | = wall motion score |
|
This article has been cited by other articles:
|
|
|
|
 
A. Miceli, R. Capoun, C. Fino, P. Narayan, A. J. Bryan, G. D. Angelini, and M. Caputo
Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Clinical Outcome in Patients Undergoing Coronary Artery Bypass Grafting
J. Am. Coll. Cardiol.,
November 3, 2009;
54(19):
1778 - 1784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Werner and M. Bohm
Review: The therapeutic role of RAS blockade in chronic heart failure
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
167 - 177.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Siegmund, P.-M. Schumm-Draeger, D. Antoni, and H. Von Bibra
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler
Diabetes and Vascular Disease Research,
December 1, 2007;
4(4):
358 - 364.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Siekmeier, C. Steffen, and W. Marz
Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations
Journal of Cardiovascular Pharmacology and Therapeutics,
December 1, 2007;
12(4):
265 - 282.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Sumukadas MBBS MD, M. D. Witham MBChB PhD, A. D. Struthers MBChB MD, and M. E.T. McMurdo MBChB MD
Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial
Can. Med. Assoc. J.,
October 9, 2007;
177(8):
867 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gianni, J. Bosch, J. Pogue, J. Probstfield, G. Dagenais, S. Yusuf, and E. Lonn
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients
Eur. Heart J.,
June 1, 2007;
28(11):
1382 - 1388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Abdulla, S. Barlera, R. Latini, L. Kjoller-Hansen, P. Sogaard, E. Christensen, L. Kober, and C. Torp-Pedersen
A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction
Eur J Heart Fail,
February 1, 2007;
9(2):
129 - 135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fox, R. Ferrari, S. Yusuf, and J. S. Borer
Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
Eur. Heart J.,
September 2, 2006;
27(18):
2154 - 2157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The HOPE and HOPE-TOO Trial Investigators
Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial
JAMA,
March 16, 2005;
293(11):
1338 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
